SCHEMBL24096605

SCHEMBL24096605

C=CCn1nc(-c2ccc(N)c(F)c2)c2c(N)ncnc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 17/20 0.69
▸ PRKDC P78527 17/20 0.69
▸ PIK3CA P42336 14/20 0.69
▸ PIK3CB P42338 14/20 0.69
▸ PIK3CG P48736 14/20 0.69
▸ ABL1 P00519 9/20 0.62
▸ EGFR P00533 9/20 0.62
▸ HCK P08631 9/20 0.62
▸ SRC P12931 9/20 0.62
▸ KDR P35968 9/20 0.62
▸ MTOR P42345 9/20 0.62
▸ EPHB4 P54760 9/20 0.62
▸ PI4KB Q9UBF8 5/20 0.62
▸ FGFR1 P11362 1/20 0.50
▸ FGFR2 P21802 1/20 0.50
▸ FGFR4 P22455 1/20 0.50
▸ FGFR3 P22607 1/20 0.50
▸ BTK Q06187 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30320520 1.00 PIK3CD (0.69) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL24096755 0.83 PIK3CD (0.62) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL29999077 0.83 PIK3CD (0.62) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL30387571 0.82 PIK3CD (1.00) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL29175926 0.82 PIK3CD (0.69) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL23997251 0.82 CYP1A2 (0.69) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL29999094 0.82 PIK3CD (0.69) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL13019688 0.81 PIK3CD (0.68) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL24096616 0.80 PRKD3 (0.58) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG
SCHEMBL24096895 0.80 PIK3CD (0.54) PIK3CDPRKDCPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 — — US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 — — US disclosed
WO-2021252488-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203045-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 PIK3CD 1435/4885PRKDC 362/4885PIK3CA 908/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 PIK3CD 3373/4885PRKDC 1450/4885PIK3CA 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback